Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and funds managed by Blackstone Life Sciences, entered a $400 million strategic funding agreement spread across four years to support the clinical development of duvakitug. Under the terms of the agreement, Blackstone will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.

Duvakitug is a human monoclonal antibody targeting TL1A, a target with the potential for broad therapeutic application across multiple indications. Under a separate and independent agreement announced in 2023, Teva is co-developing and, subject to regulatory approval, will be co-commercializing this asset with Sanofi. 

Duvakitug is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn’s disease. Both companies recently announced phase 2b duvakitug maintenance data demonstrating clinically meaningful durable efficacy in UC and CD.

“Today’s announcement highlights how we are turning strategy into action under Pivot to Growth,” said Evan Lippman, Executive Vice President, Business Development, Teva. “By pursuing disciplined, capital-efficient partnerships, we are accelerating pipeline advancement while maintaining financial strength. This is the model we will continue using to build a more innovative, resilient, and growth-oriented Teva.”